Evidence map›Paper›PMID 40648888›Full record

ReviewJournal of clinical medicine2025

Autoimmune Hepatitis and Drug-Induced Liver Injury in Japan.

Hiroki Nishikawa, Soo Ki Kim, Akira Asai

Registry-linked trialAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07644936 (Molecular Characterization of Autoimmune Hepatitis Through Lipidomic Analysis and Extracellular Vesicle Profiling), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07644936 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Molecular Characterization of Autoimmune Hepatitis Through Lipidomic Analysis and Extracellular Vesicle Profiling: A Controlled Pilot Clinical Study

TypeobservationalSponsorAzienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisRan2026 to 2028Enrolled24ConditionsAutoimmune Hepatitis, Non-Alcoholic Fatty Liver Disease
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hiroki NishikawaSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.
Soo Ki KimDepartment of Gastroenterology, Kobe Asahi Hospital, Kobe 653-8501, Hyogo, Japan.ORCID 0000-0001-5527-6555
Akira AsaiSecond Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Osaka, Japan.ORCID 0000-0002-2915-7875

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune hepatitis (AIH) is the most common liver disease caused by autoimmunity. In Japan, the number of patients with AIH has been increasing in recent years. AIH develops as a result of the loss of immune tolerance to autoantigens in the liver. Drug-induced liver injury (DILI) is an extremely important cause of liver injury in clinical practice and should always be kept in mind in the differential diagnosis. Recently, DILI caused by immune checkpoint inhibitors has been attracting attention. For the diagnosis of DILI, it is important to carefully exclude other possible causes of liver injury and obtain a detailed history of medications and the timing of their use. On the other hand, drug-induced AIH, like hepatitis, also exists and is clinically important because it is often difficult to differentiate from idiopathic AIH. A solid understanding of the pathogenesis of both AIH and DILI is essential for clinicians. This article provides an overview of AIH and DILI in Japan, including the latest findings.

Indexed as

autoimmune hepatitisdiagnosisdrug-induced liver injuryJapanpathogenesistreatment

Identifiers

PMID40648888
PMCPMC12250482

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.